By Campbell McIlroy
|
Friday 15th February 2002 |
Text too small? |
Shares in the company dropped as much as 16% in morning trading, bottoming out at $11.75 before recovering to about $12 at lunch time. Brokers said the markets had been punishing companies which failed to deliver to the level expected. "FHP did that today and was punished," one said.
Operating revenue for the three months ended December 31 was up a disappointing 1% to $55.8 million.
Analysts said increased demand in the company's core products had led to lower prices and started to squeeze the company's margins.
New products were also yet to bear fruit with some sectors already showing signs of increased competition. The company was also struck by bad luck with a mild northern winter resulting in a mild flu season and fewer humidifier sales.
One broker said it was surprising FHP hadn't given the market any indication of the sales levels it had been experiencing.
Across the three product groups FHP revealed operating revenues increased in the respiratory humidification group by 4% to $29 million, CPAP sleep apnea group was up 10% to $19.8 million and the patient warming and neonatal care group was up 9% to $3.6 million.
No comments yet
RYM - Refreshed strategy and new capital management framework
ENS - Clarification of Gina Tuzcet’s status
BGP - 4th Quarter Sales to 25 January 2026
Contact Energy 2026 Half Year Results Presentation
February 2nd Morning Report
VHP - Half year results announcement date and webcast details
Devon Funds Morning Note - 30 January 2026
AIA - Auckland Airport new board appointment
General Capital (GEN:NZ) Subsidiary General Finance Update
January 30th Morning Report